Identify the immunogenic epitope and produce monoclonal antibody against COVID-19
In recently years, monoclonal antibody play a tremendous role in therapeutic and diagnostics of many life-threatening infectious disease.44 In the year of 2019, ZMapp antibody and the antiviral agent remdesivir were dropped out due to unsuccessful potential against Ebola virus. Later on, the monoclonal antibody MAb114 and REGN-EB3 showed more than 90% survivor rate of Ebola patients.45 It was also indicated that antibodies cocktail are more effective.46 Moreover, ZIKV-195, a potently neutralizing human monoclonal antibody, has shown significant therapeutic activity against Zika virus infection in a mouse model.47
79.6% genomic sequence similarity and having the same human ACE2 receptor cells of SARS-CoV-1 and SARS-CoV-2 are the big scientific evidence opportunities. The potent neutralizing monoclonal antibody (CR3022, CR3014, m396, S230.15, R302, shown significant role in neutralization against SARS-CoV-1.48-51
Table 2. Neutralizing monoclonal antibodies against SRAS-CoV-1 and their sensitive amino acid fragments